Gastrin Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician about any test, result or symptom. Nothing here interprets an individual result, and no reference range on this page should be treated as a target.

What Gastrin Is and Where It Comes From

Gastrin is a peptide hormone produced mainly by G cells in the antral mucosa of the stomach, with smaller amounts described in the duodenum. Its principal physiological role is the stimulation of gastric acid secretion, and reviews of the gastrin–cholecystokinin peptide family have described gastrin and cholecystokinin as structurally related peptides sharing a common C-terminal sequence and acting through the CCK1 and CCK2 (CCKBR) receptors (PMID 17584137). That shared C-terminus is not a trivia point — it is one reason assay design matters, because antibodies raised against the active end of the molecule can cross-react across the family (PMID 17584137).

An analytical review of gastrin described the hormone circulating not as a single molecule but as a mixture of molecular forms of differing chain length, generated by processing of a common precursor, progastrin (PMID 14503984). The same review noted that amidated gastrin-17 and gastrin-34 are the dominant bioactive species in blood, while incompletely processed precursors also circulate (PMID 14503984). Reviews of the moderate hypergastrinaemias have described gastrin release as being governed largely by intragastric acidity, so that anything which reduces acid tends to raise gastrin through loss of negative feedback (PMID 34209478).

What the Test Actually Measures

A gastrin test is an immunoassay performed on serum or plasma. Published methodological work has stressed that the measured value depends heavily on which gastrin forms the antibody recognises. A Clinical Chemistry analysis of pitfalls in diagnostic gastrin measurement reported that commercially available assays gave markedly discrepant results on the same specimens, and that several failed to measure the full spectrum of bioactive gastrins (PMID 22419747). The authors of that work described the problem as a source of both missed and false diagnoses of gastrinoma (PMID 22419747).

The analytical review of gastrin similarly concluded that the lack of a universal calibrator and the heterogeneity of circulating forms made results non-interchangeable between laboratories (PMID 14503984). Related methodological work on the sister peptide cholecystokinin reported that accurate plasma measurement required assays specific for the bioactive amidated forms and careful preanalytical handling, and that many published nutrition studies used assays of uncertain specificity (PMID 32109763).

Why Clinicians Order a Gastrin Test, as Described in the Literature

Suspected gastrinoma and Zollinger–Ellison syndrome

The most frequently described indication is suspected gastrin-secreting tumour. A review of neuroendocrine tumour markers listed gastrin among the hormone-specific markers measured when a functioning gastroenteropancreatic neuroendocrine tumour is suspected, alongside general markers of neuroendocrine tissue (PMID 11587555). Work on pitfalls in gastrin measurement framed its findings explicitly around gastrinoma diagnosis, reporting that assay underestimation of large gastrin forms could cause tumours to be missed (PMID 22419747).

In the inherited setting, a study of patients with multiple endocrine neoplasia type 1 examined the relationship between gastrinoma and Helicobacter pylori infection and reported on the interplay between infection status and gastrin-related disease in that population (PMID 31919513).

Atrophic gastritis and vitamin B12 pathways

Gastrin is also described as a serological marker of gastric corpus atrophy. An update on serum biomarkers in autoimmune atrophic gastritis reported that elevated gastrin-17 together with low pepsinogen I and a low pepsinogen I/II ratio formed the biomarker pattern associated with corpus-restricted atrophy, and discussed parietal cell and intrinsic factor antibodies as complementary measurements (PMID 37680186). The review of moderate hypergastrinaemias likewise described chronic atrophic gastritis with achlorhydria as a classical cause of persistently raised gastrin (PMID 34209478).

Distinguishing drug effects from disease

Reviews of moderate hypergastrinaemia have emphasised that acid-suppressing therapy is among the common non-tumoural causes of raised gastrin, because reduced acidity removes the inhibitory signal on G cells (PMID 34209478). That literature treated separating drug-induced from tumour-driven elevation as a central interpretive problem rather than a footnote (PMID 34209478).

What Studies Associate With High Gastrin Levels

The review of gastrin and the moderate hypergastrinaemias grouped raised values into categories including reduced gastric acid output, renal impairment affecting peptide clearance, and antral G-cell changes, and argued that the degree of elevation alone did not identify the cause (PMID 34209478). The autoimmune atrophic gastritis biomarker review reported that hypergastrinaemia in that setting reflected loss of acid-producing parietal cells rather than autonomous hormone production (PMID 37680186).

Less obvious associations have also been published. A study in FEBS Letters reported that circulating gastrin was increased in hemochromatosis, linking iron metabolism to gastrin concentrations and noting the relevance to interpreting elevated values (PMID 17064691). Work on MEN 1 examined gastrinoma in relation to H. pylori status, a reminder that infection and tumour biology can coexist in the same patient (PMID 31919513).

• Reduced acid secretion: described as the dominant mechanism behind moderate elevations (PMID 34209478).
• Autoimmune atrophic gastritis: elevated gastrin-17 with low pepsinogen I reported as the characteristic serological pattern (PMID 37680186).
• Gastrin-secreting neuroendocrine tumour: gastrin listed among hormone-specific neuroendocrine tumour markers (PMID 11587555).
• Hemochromatosis: circulating gastrin reported as increased (PMID 17064691).
• Assay artefact: discrepant commercial kit results reported on identical specimens (PMID 22419747).

What Studies Associate With Low Gastrin Levels

Low gastrin receives far less published attention than hypergastrinaemia, and much of the available work is observational. A BMC Cancer study reported that low serum gastrin was associated with oestrogen-receptor-positive breast cancer development and described inactivation of CCKBR/ERK/P65 signalling as the proposed mechanism in that work (PMID 30115027). Researchers in that report framed the finding as an association requiring further investigation rather than a diagnostic test (PMID 30115027).

More broadly, because gastrin release is driven by gastric pH, reviews have described a high-acid environment as suppressing G-cell output, making low values physiologically expected in some settings (PMID 34209478). The analytical review cautioned that assays with poor sensitivity at the low end could not reliably distinguish genuinely low from normal-low concentrations (PMID 14503984).

Gastrin Versus Related Markers That Share the Name

Laboratory menus contain several analytes whose names resemble gastrin but measure something different. Pro-gastrin-releasing peptide (ProGRP) is a precursor of gastrin-releasing peptide, not of gastrin itself; a published evaluation reported ProGRP being used as a marker of small cell lung cancer (PMID 35737164). Another study evaluated ProGRP alongside extracellular vesicle-associated microRNA-10b and other tumour markers for lung adenocarcinoma diagnosis (PMID 34257722). Cholecystokinin is a separate peptide that shares gastrin's C-terminal sequence and requires its own specific assay (PMID 32109763; PMID 17584137).

Assay and Interpretation Caveats: What Studies Report

The methodological literature is unusually blunt about gastrin. The Clinical Chemistry pitfalls analysis reported that assay-dependent discrepancies were large enough to affect clinical conclusions, and recommended that laboratories characterise which molecular forms their method detects (PMID 22419747). The analytical review made the same point from a standardisation angle, describing calibration and antibody specificity as unresolved problems across methods (PMID 14503984).

Three further caveats recur in that literature:

1. Context changes meaning. Reviews reported that the same gastrin concentration carried different implications depending on gastric acid status and medication history (PMID 34209478).
2. Single markers rarely suffice. The autoimmune atrophic gastritis review described gastrin-17 being interpreted together with pepsinogens and autoantibodies rather than alone (PMID 37680186), and the neuroendocrine marker review described hormone-specific markers being combined with general markers (PMID 11587555).
3. Cross-reactivity is real. Shared structure between gastrin and cholecystokinin has been described as a recognised analytical challenge (PMID 17584137; PMID 32109763).

None of this translates into a number a reader can apply to a personal report. Because reference intervals are method-specific and the published literature reported substantial between-assay disagreement (PMID 22419747), interpretation of any individual gastrin result belongs with the clinician who ordered it and who knows the patient's medication, acid status and clinical picture.

Key Points

• Gastrin is an antral G-cell peptide controlling gastric acid secretion, circulating in several molecular forms (PMID 14503984).
• The test is a serum or plasma immunoassay whose result depends on which forms the antibody detects (PMID 22419747).
• Published indications include suspected gastrinoma (PMID 11587555) and atrophic gastritis assessment (PMID 37680186).
• Reduced gastric acidity is the most commonly described driver of moderate elevations (PMID 34209478).
• ProGRP is a different analyte, studied as a lung cancer marker (PMID 35737164).

References

• Gastrin and the Moderate Hypergastrinemias (International Journal of Molecular Sciences, 2021)
• Neuroendocrine tumor markers (Frontiers in Neuroendocrinology, 2001)
• Pitfalls in diagnostic gastrin measurements (Clinical Chemistry, 2012)
• Update on Serum Biomarkers in Autoimmune Atrophic Gastritis (Clinical Chemistry, 2023)
• Gastrin: an analytical review (Annals of Clinical Biochemistry, 2003)
• Measurement of cholecystokinin in plasma with reference to nutrition related obesity studies (Nutrition Research, 2020)
• Circulating gastrin is increased in hemochromatosis (FEBS Letters, 2006)
• The biology of cholecystokinin and gastrin peptides (Current Topics in Medicinal Chemistry, 2007)
• Diagnostic potential of extracellular vesicle-associated microRNA-10b and tumor markers for lung adenocarcinoma (Oncology Letters, 2021)
• Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer (Bulletin of Experimental Biology and Medicine, 2022)
• Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling (BMC Cancer, 2018)
• The Relationship of Gastrinoma in MEN 1 to Helicobacter pylori infection (Journal of Clinical Endocrinology and Metabolism, 2020)